At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 428 enrolled
Drug / intervention
losartan potassium +1 moredrug
Likely dose
losartan potassium 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Losartan Given Once or Twice Daily in Patients With Mild to Moderate Hypertension
In Brief
A Phase 3 clinical trial evaluating losartan potassium and Comparator: placebo for Hypertension. Completed, enrolled 428 participants.
Detailed Summary
The study had a 4 week single blind placebo period followed by 12 weeks of double blind treatment. Patients were randomized to one of four treatment arms to evaluate the antihypertensive efficacy of Losartan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 1992
Primary CompletionJan 1993
Study CompletionFeb 1993
First PostedApr 2009
TodayJul 2026
First PostedApr 27, 2009
Enrollment StartMay 1, 1992
Primary CompletionJan 1, 1993
Study CompletionFeb 1, 1993
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.2 years ago
Interventions
losartan potassiumdrug
losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
Comparator: placebodrug
placebo to losartan tablet q.a.m. , for 12 weeks